C4 Therapeutics Inc. (CCCC): Price and Financial Metrics
CCCC Price/Volume Stats
| Current price | $2.04 | 52-week high | $10.42 |
| Prev. close | $2.19 | 52-week low | $2.02 |
| Day low | $2.02 | Volume | 313,000 |
| Day high | $2.25 | Avg. volume | 755,909 |
| 50-day MA | $3.11 | Dividend yield | N/A |
| 200-day MA | $4.37 | Market Cap | 100.35M |
CCCC Stock Price Chart Interactive Chart >
CCCC POWR Grades
- Value is the dimension where CCCC ranks best; there it ranks ahead of 52.55% of US stocks.
- CCCC's strongest trending metric is Stability; it's been moving down over the last 179 days.
- CCCC's current lowest rank is in the Stability metric (where it is better than 7.84% of US stocks).
CCCC Stock Summary
- Of note is the ratio of C4 THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; merely 11.07% of US stocks have a lower such ratio.
- Revenue growth over the past 12 months for C4 THERAPEUTICS INC comes in at -67.98%, a number that bests merely 3.24% of the US stocks we're tracking.
- The volatility of C4 THERAPEUTICS INC's share price is greater than that of 90.36% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to C4 THERAPEUTICS INC are AEVA, FATE, RCUS, CUE, and ONCT.
- To check out C4 THERAPEUTICS INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001662579.
CCCC Valuation Summary
- CCCC's EV/EBIT ratio is -1; this is 108.06% lower than that of the median Healthcare stock.
- Over the past 36 months, CCCC's price/sales ratio has gone down 42.
Below are key valuation metrics over time for CCCC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CCCC | 2023-09-18 | 6.6 | 0.5 | -0.8 | -1.0 |
| CCCC | 2023-09-15 | 6.8 | 0.5 | -0.8 | -1.1 |
| CCCC | 2023-09-14 | 7.0 | 0.5 | -0.8 | -1.1 |
| CCCC | 2023-09-13 | 7.1 | 0.5 | -0.8 | -1.1 |
| CCCC | 2023-09-12 | 6.9 | 0.5 | -0.8 | -1.1 |
| CCCC | 2023-09-11 | 7.3 | 0.5 | -0.8 | -1.1 |
CCCC's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CCCC has a Quality Grade of C, ranking ahead of 44.43% of graded US stocks.
- CCCC's asset turnover comes in at 0.089 -- ranking 273rd of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows CCCC's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.089 | 1 | -0.411 |
| 2020-12-31 | 0.128 | 1 | -0.657 |
CCCC Price Target
For more insight on analysts targets of CCCC, see our CCCC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $61.33 | Average Broker Recommendation | 1.44 (Moderate Buy) |
C4 Therapeutics Inc. (CCCC) Company Bio
C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA.
Latest CCCC News From Around the Web
Below are the latest news stories about C4 THERAPEUTICS INC that investors may wish to consider to help them evaluate CCCC as an investment opportunity.
C4 Therapeutics Announces Chief Financial Officer SuccessionKendra Adams Kendra Adams, Chief Financial Officer WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Kendra Adams as chief financial officer (CFO), effective September 18, 2023. She will succeed Lauren White, who will be |
12 Best High Risk Penny Stocks to Buy NowIn this article, we will take a look at the 12 best high risk penny stocks to buy now. To see more such companies, go directly to 5 Best High Risk Penny Stocks to Buy Now. Investors are jubilant over Nvidia crushing analyst estimates in its latest quarterly report. Analysts are increasing their price targets […] |
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Lags Revenue EstimatesC4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 1.35% and 69.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsEstablished Exclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in Greater China for NSCLC; U.S. IND Cleared Ongoing Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC Degrader, Continue to Progress; Phase 1 Dose Escalation Data Expected 2H 2023 Strengthened Leadership Team with Appointments of Len Reyno, M.D., as Chief Medical Officer, and Mary Christian, Pharm.D., as Senior Vice President, Regulatory Ca |
With 64% institutional ownership, C4 Therapeutics, Inc. (NASDAQ:CCCC) is a favorite amongst the big gunsKey Insights Given the large stake in the stock by institutions, C4 Therapeutics' stock price might be vulnerable to... |
CCCC Price Returns
| 1-mo | -36.25% |
| 3-mo | -29.41% |
| 6-mo | -41.04% |
| 1-year | -76.17% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -65.42% |
| 2022 | -81.68% |
| 2021 | -2.81% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...